Sanofi Nabs Kymera IRAK4 Protein Degrader As It Continues To Build In I&I
Kymera will receive $150m upfront from Sanofi in a deal the big pharma views as an opportunity to develop a breakthrough oral drug for atopic dermatitis and other conditions.
You may also be interested in...
Bristol makes its own deal with Celgene ally Dragonfly, while Gilead ends virology partnerships with Durect and Precision BioSciences.
CEO Paul Hudson came to Sanofi's capital markets day with big news and key messages for investors about the company's future business model.
Gilead is elbowing its way into the protein degradation field, seeking to build out a pipeline of oncology drugs in a $45m deal with Nurix. The pool is becoming crowded though, as many other big firms have latched onto this burgeoning field of R&D.